Langley RG - Search Results

1

Secukinumab in plaque psoriasis--results of two phase 3 trials.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. Langley RG, et al. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9. N Engl J Med. 2014. PMID: 25007392 Free article. Clinical Trial.

2

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group. Lebwohl M, et al. Arch Dermatol. 2003 Jun;139(6):719-27. doi: 10.1001/archderm.139.6.719. Arch Dermatol. 2003. PMID: 12810502 Clinical Trial.

3

Psoriasis: epidemiology, clinical features, and quality of life.

Langley RG, Krueger GG, Griffiths CE. Langley RG, et al. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii18-23; discussion ii24-5. doi: 10.1136/ard.2004.033217. Ann Rheum Dis. 2005. PMID: 15708928 Free PMC article. Review.

4

Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.

Guenther L, Langley RG, Shear NH, Bissonnette R, Ho V, Lynde C, Murray E, Papp K, Poulin Y, Zip C. Guenther L, et al. Among authors: langley rg. J Cutan Med Surg. 2004 Sep-Oct;8(5):321-37. doi: 10.1007/s10227-005-0035-1. J Cutan Med Surg. 2004. PMID: 15868311

5

Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.

Langley RG, Carey WP, Rafal ES, Tyring SK, Caro I, Wang X, Wetherill G, Gordon KB. Langley RG, et al. Clin Ther. 2005 Sep;27(9):1317-28. doi: 10.1016/j.clinthera.2005.09.007. Clin Ther. 2005. PMID: 16291408 Review.

6

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Krueger GG, et al. Among authors: langley rg. Br J Dermatol. 2005 Dec;153(6):1192-9. doi: 10.1111/j.1365-2133.2005.06948.x. Br J Dermatol. 2005. PMID: 16307657 Clinical Trial.

7

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.

Papp KA, Ho V, Langley R, Lynde C, Poulin Y, Shear N, Toole J, Zip C. Papp KA, et al. J Cutan Med Surg. 2006;9 Suppl 1:26-32. doi: 10.1007/s10227-006-0104-0. J Cutan Med Surg. 2006. PMID: 16633859 Review.

8

Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.

Langley RG, Ho V, Lynde C, Papp KA, Poulin Y, Shear N, Toole J, Zip C. Langley RG, et al. J Cutan Med Surg. 2006;9 Suppl 1:18-25. doi: 10.1007/s10227-006-0103-1. J Cutan Med Surg. 2006. PMID: 16633860 Review.

9

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M; CNTO 1275 Psoriasis Study Group. Krueger GG, et al. Among authors: langley rg. N Engl J Med. 2007 Feb 8;356(6):580-92. doi: 10.1056/NEJMoa062382. N Engl J Med. 2007. PMID: 17287478 Free article. Clinical Trial.

10

Biologic therapeutics in the treatment of psoriasis. Part 1: review.

Langley RG, Gupta AK, Cherman AM, Inniss KA. Langley RG, et al. J Cutan Med Surg. 2007 May-Jun;11(3):99-122. doi: 10.2310/7750.2006.00060a. J Cutan Med Surg. 2007. PMID: 17511926 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

206 results

Search Page